Clinica Oculistica Università di Genova, Dipartimento di Neuroscienze, Oftalmologia, Genetica e Scienze Materno Infantili, Genova, Italy; Fondazione per la Macula Onlus, Genova, Italy.
Fondazione per la Macula Onlus, Genova, Italy; Clinica Oculistica - Dipartimento di Scienze Chirurgiche, Università di Torino, Torino, Italy.
Am J Ophthalmol. 2014 May;157(5):1033-7. doi: 10.1016/j.ajo.2014.01.022. Epub 2014 Jan 30.
PURPOSE: To compare the efficacy and safety of half-fluence vs half-dose photodynamic therapy (PDT) in chronic central serous chorioretinopathy (CSC). DESIGN: Multicenter retrospective comparison study. METHODS: Retrospective review of 56 patients affected by chronic CSC, including 28 patients (31 eyes) who received half-fluence PDT and 28 patients (29 eyes) who received half-dose PDT. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), and resolution of subretinal fluid on optical coherence tomography at 1 and 12 months were assessed. RESULTS: The mean logMAR BCVA improved significantly (P < .001), both in the half-fluence group (from 0.187 [± 0.187] to 0.083 [± 0.164]) and in the half-dose group (from 0.126 [± 0.091] to 0.068 [± 0.091]), at 12 months, without significant difference between the 2 groups. At 1 month a complete resolution of subretinal fluid was observed in 19 half-fluence-treated eyes (61.3%) and in 25 half-dose-treated eyes (86.2%) (P = .04). At 12 months, a complete resolution of subretinal fluid was achieved in 26 half-fluence-treated eyes (83.9%) and 29 half-dose-treated eyes (100%) (P = .0529). Nine eyes (29%) in the half-fluence group and 5 eyes (17.2%) in the half-dose group had at least 1 recurrence of subretinal fluid during the follow-up. Overall there were 15 and 5 recurrences in the half-fluence PDT and half-dose PDT groups, respectively (P = .07). In no eye of either groups was atrophy of the retinal pigment epithelium observed in the area of treatment. CONCLUSION: Half-dose PDT induced a more rapid reabsorption of the fluid, a more lasting effect, and equal safety with respect to half-fluence PDT.
目的:比较半剂量与半强度光动力疗法(PDT)治疗慢性中心性浆液性脉络膜视网膜病变(CSC)的疗效和安全性。 设计:多中心回顾性比较研究。 方法:回顾性分析 56 例慢性 CSC 患者,其中 28 例(31 眼)接受半强度 PDT 治疗,28 例(29 眼)接受半剂量 PDT 治疗。评估最佳矫正视力(BCVA)、中心视网膜厚度(CFT)和光学相干断层扫描(OCT)上 1 个月和 12 个月时视网膜下液的分辨率。 结果:两组患者的平均 logMAR BCVA 均显著提高(P<0.001),半强度组(从 0.187[±0.187]提高至 0.083[±0.164])和半剂量组(从 0.126[±0.091]提高至 0.068[±0.091]),但两组间无显著差异。1 个月时,半强度治疗组 19 只眼(61.3%)和半剂量治疗组 25 只眼(86.2%)的视网膜下液完全消退(P=0.04)。12 个月时,半强度治疗组 26 只眼(83.9%)和半剂量治疗组 29 只眼(100%)的视网膜下液完全消退(P=0.0529)。半强度治疗组 9 只眼(29%)和半剂量治疗组 5 只眼(17.2%)在随访期间至少有 1 次视网膜下液复发。半强度 PDT 组和半剂量 PDT 组分别有 15 次和 5 次复发(P=0.07)。两组均未观察到治疗区域的视网膜色素上皮萎缩。 结论:半剂量 PDT 可更快地吸收液体,效果更持久,与半强度 PDT 相比安全性相当。
Am J Ophthalmol. 2014-1-30
Graefes Arch Clin Exp Ophthalmol. 2018-11
Oman J Ophthalmol. 2025-6-24
Eye (Lond). 2025-7-4
BMC Ophthalmol. 2025-5-23
Int J Retina Vitreous. 2025-3-23
Graefes Arch Clin Exp Ophthalmol. 2025-2-11
Medicina (Kaunas). 2024-1-9